Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,381JPY
18 Aug 2017
Change (% chg)

¥-13 (-0.93%)
Prev Close
¥1,394
Open
¥1,384
Day's High
¥1,386
Day's Low
¥1,375
Volume
4,796,000
Avg. Vol
7,876,831
52-wk High
¥1,688
52-wk Low
¥1,332

Latest Key Developments (Source: Significant Developments)

Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan
Monday, 31 Jul 2017 02:38am EDT 

July 31 (Reuters) - Astellas Pharma Inc <4503.T>:* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan .  Full Article

U.S. FDA grants orphan-drug designation to Astellas
Thursday, 20 Jul 2017 08:00am EDT 

July 20 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA grants orphan-drug designation to Astellas for development of FLT3 inhibitor gilteritinib in acute myeloid leukemia.  Full Article

Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA
Wednesday, 5 Jul 2017 07:30am EDT 

July 5 (Reuters) - Cytokinetics Inc ::Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma.Cytokinetics -screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.Cytokinetics - there were no statistically significant differences otherwise in baseline demographics of enrolled patients compared to screen failures.Cytokinetics - screen failures in cohort 1 primarily due to hfmse score that was either too high in ambulatory patients or too low in non-ambulatory patients.  Full Article

Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​
Monday, 5 Jun 2017 10:45am EDT 

June 5 (Reuters) - Astellas Pharma Inc <4503.T>::Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​.Cos this year plan to initiate registrational monotherapy phase 2 trial for locally advanced/ MUC patients previously treated with CPI therapy.  Full Article

Astellas Pharma completes acquisition of Ogeda SA in Belgium
Tuesday, 16 May 2017 09:39pm EDT 

May 17(Reuters) - Astellas Pharma Inc <4503.T>:Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17.  Full Article

Astellas Pharma says transfer of 16 Long-Listed Products in Japan to LTL Pharma
Friday, 28 Apr 2017 02:54am EDT 

April 28 (Reuters) - Astellas Pharma Inc <4503.T>:* Says Astellas and LTL Pharma Co., Ltd.confirmed the relevant closing conditions are met on April 28 to allow the transfer of the assets related to Astellas’ 16 long-listed products in Japan to LTL Pharma.* Astellas and LTL Pharma have now satisfied the pre-agreed conditions to close the transaction, with Astellas having received 20.1 billion yen as a result.  Full Article

Astellas Pharma to retire treasury shares
Wednesday, 26 Apr 2017 11:23pm EDT 

April 27 (Reuters) - Astellas Pharma Inc <4503.T>:* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31.* Says the total shares outstanding is 2.07 billion shares after the retirement.  Full Article

Astellas Pharma to acquire Ogeda SA
Sunday, 2 Apr 2017 07:30pm EDT 

Astellas Pharma Inc <4503.T>: under agreement, Astellas has agreed to pay up to a total of eur 800 million . Astellas will make an initial payment of eur 500 million in consideration of 100% of equity in Ogeda at closing of transaction . Ogeda shareholders will be eligible to receive additional eur 300 million with attainment of certain milestones for fezolinetant .Astellas is still reviewing impact of this transaction on its financial forecasts for fiscal year ending March 31, 2018.  Full Article

RIBOMIC plans joint research agreement with Astellas pharma
Tuesday, 21 Mar 2017 02:30am EDT 

RIBOMIC Inc <4591.T> :Says it plans to enter into joint research agreement with Astellas pharma Inc <4503.T>, regarding R&D of aptamers pharmaceuticals.  Full Article

X-Chem signs broad drug discovery collaboration with Astellas Pharma
Monday, 20 Mar 2017 08:15am EDT 

X-Chem Inc: X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc . X-Chem Inc - under terms of this multi-year agreement, X-Chem will receive an up-front payment of $16 million . X-Chem Inc - as per agreement, co is eligible to receive research funding, as well as license and option fees as drug discovery collaboration proceeds . X-Chem - additionally, Astellas has option to license compounds identified through the collaboration . X-Chem - co will be entitled to pre-clinical, developmental, and commercial milestone payments on licensed compounds against each target .X-Chem - milestone payments could amount to over $100 million per target, in addition to royalties based on sales of future products.  Full Article

BRIEF-Astellas Pharma submits application for approval of fidaxomicin for the treatment of infectious enteritis in Japan

* Says it has submitted an application for marketing approval of fidaxomicin for the treatment of infectious enteritis in Japan